hypericum and Dysthymic-Disorder

hypericum has been researched along with Dysthymic-Disorder* in 3 studies

Reviews

1 review(s) available for hypericum and Dysthymic-Disorder

ArticleYear
[Treatment of dysthymia].
    Praxis, 2000, Dec-21, Volume: 89, Issue:51-52

    Hippocrates described both melancholy and dysthymia. An episode of mild depression lasting up to 2 years, which does not make patients unfit to work, although the repressive irritative mood disorder does reduce their ability to work. Severe depressive moods can develop from dysthymia. While dysthymia responds to antidepressant treatment similarly to depressive episodes, treatment must be carried out for a considerably longer period. The dosage dose not differ from that for severe depressive episodes. A few examples of cases are presented from the speaker's own cases to illustrate how well they responded to treatment with St.-John's wort.

    Topics: Antidepressive Agents; Dysthymic Disorder; Humans; Hypericum; Long-Term Care; Phytotherapy; Plants, Medicinal; Treatment Outcome

2000

Trials

1 trial(s) available for hypericum and Dysthymic-Disorder

ArticleYear
The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2006, Volume: 13, Issue:4

    We studied the efficacy of St. John's Wort compared with placebo in patients with minor depressive symptoms or dysthymia, with the main focus on which diagnostic entities are optimally amenable to treatment with two different doses of Hypericum, and which are not.. One hundred and fifty patients, 25-70 years old, meeting ICD-10 criteria for mild or moderately severe depressed episodes or with dysthymia, and having a 17-item Hamilton Depression Scale for Depression (HAM-D) total score between 7 and 17, were randomly assigned to an extract. The extract, PM235, manufactured by Cederroth International AB, Sweden, was given t.i.d. in a lower (0.12% hypericine) or a higher (0.18% hypericine) formulation, based on 270mg extractions or identical placebo. Clinical response was defined by HAM-D as a 50% reduction and/or a score 7. The Beck Depression Inventory (BDI) and Visual Analog Scales (VAS) were used as secondary efficacy parameters. Measures were conducted at screening, baseline, and after 3 and 6 weeks of treatment.. We found a large discrepancy in response between dysthymic and non-dysthymics, the latter seemingly more sensitive to Hypericum. HAM-D showed tendency but no significance toward a more frequent improvement of the non-dysthymics treated with Hypericum (p=0.057). BDI criteria showed significance (p=0.045) for both doses of Hypericum compared to placebo. Pooling high- and low-dose groups together, a significant reduction for HAM-D7 and BDI criteria was found among non-dysthymic patients (p=0.03). Significant improvement in response to Hypericum was found in symptoms reflected by VAS - again only in non-dysthymic patients (p=0.041).. We observed, a tendency toward a more frequent significant improvement of the non-dysthymic patient treated with PM235, though this did not reach the level of statistical significance. In a secondary analysis, pooling both hypericine-treated groups concluded that Hypericum has a clinical significant effect in minor depressed patients with HAM-D up to 17. This finding was significant only in non-dysthymic patients.

    Topics: Adult; Aged; Depression; Double-Blind Method; Dysthymic Disorder; Female; Humans; Hypericum; Male; Middle Aged; Phytotherapy; Plant Extracts; Time Factors

2006

Other Studies

1 other study(ies) available for hypericum and Dysthymic-Disorder

ArticleYear
Implications of self-administered St. John's wort for depression symptom management.
    Journal of the American Academy of Nurse Practitioners, 2002, Volume: 14, Issue:10

    To provide nurse practitioners (NPs) with a greater understanding of the complex issues surrounding St. John's wort as a self-treatment for depression; to review laws regulating the production and sale of herbal products in the United States (U.S.); and to review clinical and practice implications for the self-administration of St. John's wort and herbal treatments.. Federal regulations pertaining to herbal products, current research literature, and anecdotal and consumer reports.. Current research findings suggest that St. John's wort may be an effective treatment for mild depression; however, evidence of significant adverse drug interactions with St. John's wort should not be overlooked.. Clinical assessment of the mildly depressed patient wishing to self-administer St. John's wort requires basic knowledge of this herbal supplement including regulation and risk information. An open NP-patient relationship helps to ensure patient disclosure of self-administered St. John's wort.

    Topics: Depression; Drug Interactions; Dysthymic Disorder; Humans; Hypericum; Phytotherapy; Plant Preparations; Self Medication

2002